APA

Sacchi S., Federico M., Vitolo U., Boccomini C., Vallisa D., Baldini L., Petrini M., Rupoli S., Di Raimondo F., Merli F., Liso V., Tabilio A., Saglio G., Vinci G., Brugiatelli M. & Dastoli G. (20020925). Clinical activity and safety of combination immunotherapy with IFN-alpha 2a and Rituximab in patients with relapsed low grade non-Hodgkin's lymphoma. : Haematologica.

Chicago

Sacchi S, Federico M, Vitolo U, Boccomini C, Vallisa D, Baldini L, Petrini M, Rupoli S, Di Raimondo F, Merli F, Liso V, Tabilio A, Saglio G, Vinci G, Brugiatelli M and Dastoli G. 20020925. Clinical activity and safety of combination immunotherapy with IFN-alpha 2a and Rituximab in patients with relapsed low grade non-Hodgkin's lymphoma. : Haematologica.

Harvard

Sacchi S., Federico M., Vitolo U., Boccomini C., Vallisa D., Baldini L., Petrini M., Rupoli S., Di Raimondo F., Merli F., Liso V., Tabilio A., Saglio G., Vinci G., Brugiatelli M. and Dastoli G. (20020925). Clinical activity and safety of combination immunotherapy with IFN-alpha 2a and Rituximab in patients with relapsed low grade non-Hodgkin's lymphoma. : Haematologica.

MLA

Sacchi S, Federico M, Vitolo U, Boccomini C, Vallisa D, Baldini L, Petrini M, Rupoli S, Di Raimondo F, Merli F, Liso V, Tabilio A, Saglio G, Vinci G, Brugiatelli M and Dastoli G. Clinical activity and safety of combination immunotherapy with IFN-alpha 2a and Rituximab in patients with relapsed low grade non-Hodgkin's lymphoma. : Haematologica. 20020925.